A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

NCT06267001 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Atezolizumab
DRUG: Tiragolumab
DRUG: Placebo

Sponsor

Hoffmann-La Roche